Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer

Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

10.1200/jco.2008.26.15_suppl.8061 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8061-8061 ◽

Cited By ~ 2

Author(s):

D. M. Kocs ◽

R. N. Raju ◽

M. A. Socinski ◽

T. E. Stinchcombe ◽

S. R. Rousey ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).

10.1200/jco.2010.28.15_suppl.7576 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7576-7576 ◽

Cited By ~ 1

Author(s):

T. Stinchcombe ◽

D. S. Bradford ◽

C. B. Lee ◽

D. T. Moore ◽

K. M. Bakri ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

10.1200/jco.2015.33.15_suppl.8056 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8056-8056

Author(s):

Masayuki Takeda ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Morihito Okada ◽

Koichi Azuma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

10.1097/jto.0b013e3181fd42eb ◽

2010 ◽

Vol 5 (12) ◽

pp. 1963-1969 ◽

Cited By ~ 25

Author(s):

Mark A. Socinski ◽

Robert N. Raju ◽

Thomas Stinchcombe ◽

Darren M. Kocs ◽

Linda S. Couch ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-006-0358-7 ◽

2006 ◽

Vol 60 (1) ◽

pp. 143-150 ◽

Cited By ~ 12

Author(s):

D. Binder ◽

H. Schweisfurth ◽

C. Grah ◽

C. Schäper ◽

B. Temmesfeld-Wollbrück ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

10.1097/jto.0b013e3182307efe ◽

2012 ◽

Vol 7 (1) ◽

pp. 196-202 ◽

Cited By ~ 23

Author(s):

David R. Spigel ◽

John D. Hainsworth ◽

Dianna L. Shipley ◽

Thomas J. Ervin ◽

Peter C. Kohler ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

10.1200/jco.2011.29.15_suppl.7504 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7504-7504 ◽

Cited By ~ 6

Author(s):

M. Thomas ◽

A. Reuss ◽

J. R. Fischer ◽

S. Andreas ◽

C. Kortsik ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer

10.1097/jto.0b013e3182210430 ◽

2011 ◽

Vol 6 (9) ◽

pp. 1569-1577 ◽

Cited By ~ 26

Author(s):

Thomas E. Stinchcombe ◽

Amy H. Peterman ◽

Carrie B. Lee ◽

Dominic T. Moore ◽

Jennifer L. Beaumont ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

10.1200/jco.2010.28.15_suppl.7593 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7593-7593

Author(s):

D. R. Spigel ◽

F. A. Greco ◽

D. Shipley ◽

T. J. Ervin ◽

E. T. Lubiner ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

P48.09 Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial

10.1016/j.jtho.2021.01.879 ◽

2021 ◽

Vol 16 (3) ◽

pp. S503

Author(s):

B. Han ◽

W. Zhang ◽

B. Zhang ◽

Y. Chen ◽

Y. Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Extensive Stage ◽